Replimune Group (NASDAQ:REPL) Trading Up 6.4% – Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL) shot up 6.4% during trading on Wednesday . The company traded as high as $8.76 and last traded at $8.94. 291,629 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 858,083 shares. The stock had previously closed at $8.40.

Analyst Ratings Changes

A number of equities analysts have issued reports on REPL shares. BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, HC Wainwright upped their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $19.43.

Replimune Group Stock Down 5.4 %

The company has a market capitalization of $574.53 million, a PE ratio of -2.43 and a beta of 1.26. The stock’s fifty day moving average is $12.39 and its two-hundred day moving average is $12.09. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its stake in Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after acquiring an additional 52,498 shares during the period. Geode Capital Management LLC increased its stake in shares of Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after purchasing an additional 217,308 shares in the last quarter. Barclays PLC raised its position in shares of Replimune Group by 165.5% in the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after purchasing an additional 98,791 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Replimune Group during the 4th quarter valued at approximately $543,000. Finally, State Street Corp boosted its holdings in Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after buying an additional 1,182,181 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.